Given the very positive sales momentum observed in the first half of the year (revenue growth expected to be around 16% at constant exchange rates1 and ~11% at constant exchange rates and scope), which is set to continue in the second half of the year, as well as a particularly buoyant animal health market, 2024 revenue growth at constant exchange rates is expected to be between 12.5% and 14.5%¹ (corresponding to a growth at constant exchange rates and scope now expected  between 7% to 9%). 

The ratio of "current operating income before depreciation of assets resulting from acquisitions'' to "revenue" should consolidate at around 16% at constant exchange rates and scope. At actual scope, the impact of the Sasaeah and Globion acquisitions should be slightly accretive on this ratio. 

¹ Including the impact of the acquisitions of Sasaeah in Japan and Globion in India
 

GO BACK